Kazia Therapeutics Limited (KZIA)
Kazia Therapeutics Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Kazia Therapeutics Limited (KZIA) is a Biotechnology company based in AU with a market capitalization of $19.9M. Revenue declined 98.2% year-over-year and free cash flow was negative at -$9.2M. This page tracks KZIA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
AU · 9 employees · IPO Jan 6, 1999
Valuation
Valuation & price
$13.16as of May 17, 2026· -16.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$19.9M
Market cap
-98.2%
Revenue growth (YoY)
100.0%
Gross margin
-$9.2M
Free cash flow (USD)
-$3.9M
Net debt
Net cash position
128.4%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: —
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Kazia Therapeutics Limited's market cap?
Kazia Therapeutics Limited (KZIA) has a market capitalization of $19.9M.
What is KZIA's P/E ratio?
A meaningful P/E ratio is not available for KZIA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying KZIA stock?
SEC Form 4 filings show no open-market insider buys at Kazia Therapeutics Limited in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.